Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.

In December, Vertex's CASGEVY gained regulatory approval in the UAE for sickle cell disease and transfusion-dependent beta-thalassemia. Suzetrigine for moderate-to-severe acute pain awaits an FDA ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...